Strategic Asset Sale Tetralogic Pharmaceuticals completed a significant asset sale to Medivir AB in 2016, indicating a strategic transition that could open new partnership or licensing opportunities for companies in biotech and pharmaceutical sectors interested in oncology assets.

Clinical Pipeline Focus With two clinical-stage product candidates, birinapant and SHAPE, Tetralogic is actively progressing in oncology and infectious disease treatments, presenting opportunities for collaboration, clinical trial support, or research partnerships.

Financial Stability Possessing a funding pool of $47 million and generating revenues between $10 million and $25 million, the company has a stable financial position that supports ongoing research and potential partnering opportunities for investors or service providers.

Niche Market Presence Operating with a small team of fewer than 50 employees in biotechnology research, Tetralogic offers a targeted customer profile for specialized equipment, research services, or technology solutions tailored for midsize biotech firms.

Technology and Digital Presence Utilizing standard web technologies and digital marketing tools, Tetralogic maintains an active online presence, creating potential for digital marketing collaborations, content services, or technological solution pitches to enhance their outreach and research dissemination.